索利那新联合坦索罗辛预防尿管相关膀胱不适的疗效分析

唐国强; 肖敏; 刘健; 魏勇

doi:10.13201/j.issn.1001-1420.2019.12.015

索利那新联合坦索罗辛预防尿管相关膀胱不适的疗效分析

- 重庆市九龙坡区第二人民医院泌尿外科(重庆, 400052)
基金项目:
重庆市卫生计生委医学科研项目（编号2017ZBXM017）

详细信息

通讯作者: 肖敏,E-mail:752451802@qq.com

中图分类号: R699

收稿日期: 2018-10-31

Evaluation of the efficacy of combined solifenacin and tamsulosin for prevention of catheter-related bladder discomfort

- Department of Urology, Second People's Hospital in Jiulongpo District, Chongqing, 400052, China

More Information

Corresponding author: XIAO Min, E-mail: 752451802@qq.com

Received Date: 31 October 2018

摘要

摘要: 目的：比较索利那新联合或不联合坦索罗辛用于预防尿管相关膀胱不适（CRBD）的有效性及安全性。方法：选取100例需全麻下行输尿管软镜碎石术并留置导尿的患者，随机分为联合用药组和对照组，每组50例。联合用药组麻醉诱导前2 h口服索利那新5.0 mg+坦索罗辛0.2 mg，对照组麻醉诱导前口服索利那新5.0 mg。术后患者被送入麻醉恢复室，分别在到达恢复室0、1、2、6 h评估CRBD发生率、严重程度及视觉疼痛评分（VAS）。结果：研究显示联合用药组苏醒期0、1、2、6 h CRBD发生率为56.0%、60.0%、54.0%、42.0%，对照组苏醒期0、1、2、6 h CRBD发生率为72.0%、72.0%、68.0%、60.0%，两组比较差异无统计学意义（P>0.05）。联合用药组苏醒期0、1、2、6 h CRBD的严重程度及VAS评分均明显低于对照组，差异有统计学意义（P<0.05）。两组患者并发症口干（10.0% vs.8.0%）、恶心/呕吐（6.0% vs.12.0%）发生率比较差异无统计学意义（P>0.05）。结论：尽管索利那新联合坦索罗辛不能显著降低患者CRBD的发生率，但联合用药能有效降低患者CRBD的严重程度及VAS评分。
- 尿管相关膀胱不适 /
- 索利那新 /
- 坦索罗辛
Abstract: Objective: To compare the efficacy and safety between combined solifenacin and tamsulosin and only solifenacin for prevention of catheter-related bladder discomfort(CRBD). Method: A total of 100 patients undergoing flexible ureteroscopic lithotripsy with urinary catheter were equally divided into two groups by random. Combined drug group received oral solifenacin 5 mg and tamsulosin 0.2 mg and control group received solifenacin 5 mg 2 hours prior to induction of anesthesia. Patients' visual analog scale(VAS), the incidence and severity of CRBD were evaluated at 0, 1, 2 and 6 h after patient's arrival in the post-anaesthesia care unit for statistical analysis. Result: The incidence of CRBD in the combined drug group and in the control group were 56.0%, 60.0%, 54.0%, 42.0% and 72.0%, 72.0%, 68.0%, 60.0% at 0, 1, 2 and 6 h, respectively. There was no statistical difference between two groups. The severity of CRBD observed in the combined drug group were significantly lower than those in the control group at 0, 1, 2 and 6 h after patient's arrival in the post-anaesthesia care unit(P<0.05). VAS were significantly lower in the combined drug group than those in the control group(P<0.05). However, no significant difference could be found between the two groups in dry mouth(10.0% vs. 8.0%) and nausea/vomiting(6.0% vs. 12.0%, P>0.05).Conclusion: Although combined solifenacin and tamsulosin could not significantly reduce the incidence of CRBD in patients, it could significantly reduce the severity of CRBD and VAS in the early postoperative period.
- catheter-related bladder discomfort /
- solifenacin /
- tamsulosin

HTML全文

参考文献(18)

[1]	Akça B, Aydoǧan-Eren E, Canbay Ö, et al.Comparison of efficacy of prophylactic ketamine and dexmedetomidine on postoperative bladder catheter-related discomfort[J].Saudi Med J, 2016, 37(1):55-59.
[2]	Kim J A, Min J H, Lee H S, et al.Effects of glycopyrrolate premedication on preventing postoperative catheter-related bladder discomfort in patients receiving ureteroscopic removal of ureter stone[J].Korean J Anesthesiol, 2016, 69(6):563-567.
[3]	Bai Y, Wang X, Li X, et al.Management of catheterrelated bladder discomfort in Patients Who Underwent Elective Surgery[J].J Endourol, 2015, 29(6):640-649.
[4]	Kim H C, Lee Y H, Jeon Y T, et al.The effect of intraoperative dexmedetomidine on postoperative catheter-related bladder discomfort in patients undergoing transurethral bladder tumour resection:A double-blind randomised study[J].Eur J Anaesthesiol, 2015, 32(9):596-601.
[5]	Zhang Z, Cao Z, Xu C, et al.Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors[J].Urology, 2014, 84(1):117-121.
[6]	范治璐, 鞠红卫, 李传刚, 等.索利那新加坦索罗辛治疗膀胱过度活动症的疗效分析[J].中华泌尿外科杂志, 2011, 32(8):532-534.
[7]	Kunin C M.Nosocomial urinary tract infections and the indwelling catheter:what is new and what is true?[J].Chest, 2001, 120(1):10-12.
[8]	Binhas M, Motamed C, Hawajri N, et al.Predictors of catheter-related bladder discomfort in the post-anaesthesia care unit[J].Ann Fr Anesth Reanim, 2011, 30(2):122-125
[9]	Srivastava V K, Agrawal S, Kadiyala V N, et al.The efficacy of pregabalin for prevention of catheter-related bladder discomfort:a prospective, randomized, placebo-controlled double-blind study[J].J Anesth, 2015, 29(2):212-216.
[10]	Kim J A, Min J H, Lee H S, et al.Effects of glycopyrrolate premedication on preventing postoperative catheter-related bladder discomfort in patients receiving ureteroscopic removal of ureter stone[J].Korean J Anesthesiol, 2016, 69(6):563-567.
[11]	Wilson M.Causes and management of indwelling urinary catheterrelated pain[J].Br J Nurs, 2008, 17(4):232-239.
[12]	Safavi M, Honarmand A, Atari M, et al.An evaluation of the efficacy of different doses of ketamine for treatment of catheter-related bladder discomfort in patients underwent urologic surgery:A prospective, randomized, placebo-controlled, double-blind study[J].Urol Ann, 2014, 6(1):51-56.
[13]	黄建华, 彭波, 刘敏, 等.经尿道双极等离子前列腺切除术治疗BPH继发OAB的疗效观察[J].临床泌尿外科杂志, 2017, 32(1):51-53.
[14]	邢增术, 肖亚军, 梁培育, 等.坦索罗辛联合索利那新治疗BPH伴膀胱过度活动症的临床观察[J].临床泌尿外科杂志, 2012, 27(2):133-135.
[15]	Verma R, Agarwal A, Singh P K, et al.Evaluation of efficacy of amikacin for attenuation of catheter-related bladder discomfort in patients undergoing percutaneous nephrolithotomy:A prospective, randomized, placebo-controlled, double-blind study[J].Anesth Essays Res, 2016, 10(3):613-617.
[16]	Srivastava V K, Nigam R, Agrawal S, et al.Evaluation of the efficacy of solifenacin and darifenacin for prevention of catheter-related bladder discomfort:a prospective, randomized, placebo-controlled, double-blind study[J].Minerva Anestesiol, 2016, 82(8):867-873.
[17]	杨宇, 谢辉, 郑建建, 等.α1肾上腺素能受体亚型在慢性前列腺炎前列腺、后尿道及膀胱逼尿肌组织中的分布及其意义[J].中华医学杂志, 2010, 90(46):3268-3271.
[18]	吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社, 2004:118-118.